Naftopidil - Wikipedia
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hyperplasia which acts as a selective α 1 -adrenergic receptor antagonist or alpha-1 blocker. [1] The reaction of 1-naphthol (1) with epichlorohydrin (2) in …
萘哌地尔 - 百度百科
萘哌地尔，是一种有机化合物，化学式为C24H28N2O3，主要用作α1肾上腺素受体阻滞药，能够抑制α1受体引起的血压上升，并兼有钙离子拮抗作用，药效学试验表明，本品对多种高血压动物模型有降压作用，降压持续时间长，降压时不引起反射性心动过速，多次口服给药未见明显的首剂效应和耐药现象。 那妥萘哌地尔是一种新型的长效、高选择性的α1-受体阻滞剂，通过选择性地作用于α1A和α1D受体，能够缓解该受体兴奋所致的前列腺和尿道的交感神经性紧张、降低尿道内 …
Naftopidil for the treatment of lower urinary tract symptoms …
2018年10月11日 · Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term) Participants: men with lower urinary tract symptoms suggesting benign prostatic hyperplasia Setting: likely outpatients Intervention: naftopidil Comparator: propiverine: Outcomes № of ...
Naftopidil for the treatment of urinary symptoms in patients with ...
2011年6月23日 · Naftopidil, approved only in Japan, is an α1-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Naftopidil: Uses, Interactions, Mechanism of Action - DrugBank …
Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.
NAFTOPIDIL - National Center for Advancing Translational Sciences
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective alpha1-adrenergic receptor antagonist, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS).
Naftopidil for the treatment of lower urinary tract symptoms …
Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease-related complications. Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting.
Naftopidil | C24H28N2O3 | CID 4418 - PubChem
Naftopidil | C24H28N2O3 | CID 4418 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
Naftopidil - an overview | ScienceDirect Topics
2014年1月3日 · Naftopidil is a potent postsynaptic-selective alpha-1-antagonist that was launched for the treatment of dysuria associated with benign prostatic hypertrophy.
Naftopidil for the treatment of benign prostate hyperplasia: a ...
Although additional well designed, worldwide, placebo-controlled and randomized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy, current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS, QoL, and urinary symptoms from baseline relative to 0.2 mg/d ...